The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry

Antoinetta J. M. Beijers*, Simone Oerlemans, Floortje Mols, Marijke Eurelings, Monique C. Minnema, Art Vreugdenhil, Lonneke V. van de Poll-Franse

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)653-663
Number of pages11
JournalAnnals of Hematology
Volume96
Issue number4
DOIs
Publication statusPublished - Apr 2017

Keywords

  • Chemotherapy-induced peripheral neuropathy
  • Neuropathy
  • Treatment
  • Dose modification
  • Multiple myeloma
  • QUALITY-OF-LIFE
  • INDUCED PERIPHERAL NEUROPATHY
  • COMMON TERMINOLOGY CRITERIA
  • PROTEASOME INHIBITOR
  • ADVERSE EVENTS
  • BORTEZOMIB
  • QUESTIONNAIRE
  • REVERSIBILITY
  • DEXAMETHASONE
  • LENALIDOMIDE

Cite this

Beijers, A. J. M., Oerlemans, S., Mols, F., Eurelings, M., Minnema, M. C., Vreugdenhil, A., & van de Poll-Franse, L. V. (2017). The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. Annals of Hematology, 96(4), 653-663. https://doi.org/10.1007/s00277-017-2927-8